Cellectar Biosciences (FRA:NV4) Total Liabilities : €15.40 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Total Liabilities?

Cellectar Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 was €15.40 Mil.

Cellectar Biosciences's quarterly Total Liabilities declined from Sep. 2023 (€32.71 Mil) to Dec. 2023 (€12.32 Mil) but then increased from Dec. 2023 (€12.32 Mil) to Mar. 2024 (€15.40 Mil).

Cellectar Biosciences's annual Total Liabilities increased from Dec. 2021 (€3.68 Mil) to Dec. 2022 (€5.74 Mil) and increased from Dec. 2022 (€5.74 Mil) to Dec. 2023 (€12.32 Mil).

Cellectar Biosciences Total Liabilities Historical Data

The historical data trend for Cellectar Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Total Liabilities Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.87

3.18

3.68

5.74

12.32

Cellectar Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															7.01	6.44	32.71	12.32	15.40

Cellectar Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cellectar Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.864	+	(0.453	+	-6.1062266354384E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.32

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11.074	-	-1.243
	=	12.32

Cellectar Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.967	+	(0.436	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	15.40

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	39.475	-	24.073
	=	15.40

Cellectar Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CLRB:USA

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines